TRIAL DETAIL
Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery |
|||
NCT#: |
||||
Conditions: |
Gastrointestinal Stromal Tumor |
|||
Status: |
Active, not recruiting |
|||
Phase: |
2 |
Start Date 12/01/2016 |
Age of Trial (yrs) 8 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
PD-1 inhibitor + CTLA-4 inhibitor |
|||
Strategy: |
Immunotherapy |
|||
Trial Type: |
Specifically GIST and only GIST |
|||
Other Protocol IDs: |
16-000525 NCI-2016-01004 16-000525 P30CA016042 US NIH Grant |
|||
Sponsor: |
Johnson Comprehensive Cancer center |
|||
Patient Contact: |
Arun Singh
310-829-5471 asingh@mednet.ucla.edu |
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
Randomized |
|||
IV or Oral: |
Subcutaneous |
|||
Trial Notes: |
Collaborator: National Cancer Institute |
|||
Trial Links |
Trial Results |
Drug Information |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
10945 Le Conte Ave. |
Los Angeles |
CA |
90095 |
USA |